News

Published on 4 Feb 2023 on Simply Wall St. via Yahoo Finance

Immuneering Corporation (NASDAQ:IMRX) insiders, who hold 31% of the firm would be disappointed by...


Article preview image

To get a sense of who is truly in control of Immuneering Corporation (NASDAQ:IMRX), it is important to understand the ownership structure of the business. We can see that individual insiders own the lion's share in the company with 31% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

And following last week's 11% decline in share price, insiders suffered the most losses.

NASDAQ.IMRX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Immuneering Director Acquires 7.5% More Stock

Potential Immuneering Corporation (NASDAQ:IMRX) shareholders may wish to note that the Director, ...

Simply Wall St. via Yahoo Finance 21 Mar 2024

Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks...

Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stock...

Investing.com 18 Mar 2024

Immuneering (IMRX) Plummets 71% in One Week: Here's Why

Immuneering Corporation IMRX is a clinical-stage biotech company focused on developing universal-...

Zacks via Yahoo Finance 18 Mar 2024

Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor...

Thursday, Immuneering Corporation IMRX revealed topline results from the ongoing Phase 1 portion ...

Benzinga 15 Mar 2024

Crude Oil Edges Lower; US Consumer Sentiment Falls In March - Cardlytics (NASDAQ:CDLX), American...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points...

Benzinga 15 Mar 2024

Immuneering stock downgraded by Jefferies on Lackluster Phase 1 Data By Investing.com

Immuneering stock downgraded by Jefferies on Lackluster Phase 1 Data

Investing.com 15 Mar 2024

Immuneering stock target cut to $15 by Needham

Immuneering stock target cut to $15 by Needham

Investing.com 15 Mar 2024

Immuneering stock price target cut to $16 from $21

On Friday, Chardan Capital Markets adjusted its price target forImmuneering Corporation (NASDAQ:I...

Investing.com 15 Mar 2024

Why Is Immuneering Stock Trading Lower Today? - Immuneering (NASDAQ:IMRX)

Thursday, Immuneering Corporation IMRX revealed topline results from the ongoing Phase 1 portion ...

Benzinga 14 Mar 2024

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In...

Shares of Limbach Holdings, Inc. LMB fell sharply during Thursday’s session after the company re...

Benzinga 14 Mar 2024